Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Peter A. Thompson FACP, M.D. | Co-Founder & Independent Chairman | 76k | -- | 1960 |
| Dr. Kevin Koch Ph.D. | President, CEO & Director | 905.52k | -- | 1960 |
| Dr. Badreddin Edris Ph.D. | Co-Founder & Independent Director | 43k | -- | 1988 |
| Dr. Behrad Derakhshan Ph.D. | Chief Operating Officer | 630.67k | -- | 1980 |
| Dr. Joanne M. Donovan M.D., Ph.D. | Chief Medical Officer | 696.4k | -- | 1957 |
| Dr. Alan J. Russell Ph.D. | Co-Founder, Chief Scientific Officer & Director | 657.52k | -- | 1970 |
| Mr. R. Michael Carruthers | Chief Financial Officer | 386.01k | -- | 1958 |
| Mr. John R. Moore J.D. | General Counsel | -- | -- | 1964 |
| Dr. Robert Blaustein M.D., Ph.D. | Chief Development Officer | -- | -- | -- |
Edgewise Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 110
Description
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
Corporate Governance
Upcoming Events
May 7, 2025 at 12:30 PM UTC - May 12, 2025 at 12:30 PM UTC
Edgewise Therapeutics, Inc. Earnings Date